Spotlight On: Biosimilar Litigations - March 2026

Why It Matters

Clear definitions help pharmaceutical companies and counsel assess litigation risk and allocate resources efficiently, shaping competitive strategies in the fast‑growing biosimilar market.

Key Takeaways

• Defines biosimilar litigation scope.
• Includes applicant vs. sponsor disputes.
• Covers inter‑applicant biosimilar conflicts.
• Excludes reference‑to‑reference lawsuits.
• Omits pure manufacturing patent cases.

Pulse Analysis

The biosimilar sector is entering a pivotal growth phase, with dozens of follow‑on products seeking FDA approval each year. As market entry accelerates, so does the frequency of patent challenges and settlement negotiations, making litigation a core component of commercial strategy. Companies must therefore understand not only the scientific equivalence of their products but also the legal contours that define which disputes fall under the biosimilar umbrella.

Venable LLP’s March 2026 briefing draws a precise line around what qualifies as a biosimilar litigation. By limiting the scope to disputes involving biosimilar applicants or manufacturers against reference‑product sponsors—and between competing biosimilar developers—the firm provides a practical filter for counsel assessing case relevance. The exclusion of reference‑to‑reference fights and pure manufacturing‑patent battles, such as those involving the Cabilly patents, prevents over‑broad litigation risk assessments and focuses resources on the most consequential battles.

For industry stakeholders, this delineation translates into more disciplined risk management and clearer budgeting for legal expenses. Companies can now prioritize defending or challenging patents that directly affect product launch timelines, while deprioritizing peripheral manufacturing‑patent issues. The guidance also signals to investors that firms with robust biosimilar litigation strategies are better positioned to capture market share, reinforcing the importance of specialized legal expertise in an increasingly competitive biologics landscape.